IBMP - Institute for Biomedical and Pharmaceutical Research, Nürnberg-Heroldsberg, Germany.
Antimicrob Agents Chemother. 2012 Nov;56(11):5715-23. doi: 10.1128/AAC.00937-12. Epub 2012 Aug 20.
Piperacillin in combination with tazobactam is one of the most commonly used intravenous antibiotics. There is evidence for a possible saturable elimination of piperacillin. Therefore, the saturable elimination and its impact on the choice of optimal dosage regimens were quantified. In a randomized crossover study, 10 healthy volunteers received 1,500 mg and 3,000 mg of piperacillin as 5-min intravenous infusion. Population pharmacokinetics based on plasma and urine data were determined utilizing NONMEM and S-ADAPT. Probabilities of target attainment (PTAs) were compared for different models and dosage regimens, based on the target time of the non-protein-bound concentration above the MIC of at least 50% of the dosing interval. Total clearance of piperacillin was 18% (geometric mean ratio, 90% confidence interval, 11 to 24%) lower (P < 0.01), and renal clearance was 24% (9 to 37%) lower (P = 0.02) at the high compared to the low dose. The final model included first-order nonrenal elimination and parallel first-order and mixed-order renal elimination. Nonrenal clearance was 5.44 liter/h (coefficient of variation, 18%), first-order renal clearance was 4.42 liter/h (47%), and the maximum elimination rate of mixed-order renal elimination was 219 mg/h (84%), with a Michaelis-Menten constant of 36.1 mg/liter (112%). Compared to models with saturable elimination, a linear model predicted up to 10% lower population PTAs for high-dose short-term infusions (6 g every 8 h) and up to 4% higher population PTAs for low-dose continuous infusions (6 g/day). While renal elimination of piperacillin was saturable at therapeutic concentrations, the extent of saturation of nonrenal clearance was small. The influence of saturable elimination on PTAs for clinically relevant dosage regimens was relatively small.
哌拉西林他唑巴坦是最常用的静脉用抗生素之一。有证据表明哌拉西林可能存在饱和消除。因此,本研究旨在定量评估哌拉西林的饱和消除及其对最佳剂量方案选择的影响。在一项随机交叉研究中,10 名健康志愿者接受了 1500mg 和 3000mg 的哌拉西林,以 5 分钟静脉输注。利用 NONMEM 和 S-ADAPT 基于血浆和尿液数据确定群体药代动力学。基于非蛋白结合浓度在 MIC 以上的时间达到目标的 50%以上的目标时间,比较了不同模型和剂量方案的目标浓度达标概率(PTAs)。与低剂量相比,高剂量时哌拉西林总清除率降低 18%(几何均数比,90%置信区间为 11%至 24%)(P < 0.01),肾清除率降低 24%(9%至 37%)(P = 0.02)。最终模型包括一级非肾消除和平行一级和混合级肾消除。非肾清除率为 5.44 升/小时(变异系数 18%),一级肾清除率为 4.42 升/小时(47%),混合级肾消除的最大消除率为 219 毫克/小时(84%),米氏常数为 36.1 毫克/升(112%)。与饱和消除模型相比,线性模型预测高剂量短期输注(每 8 小时 6g)的群体 PTA 低 10%,低剂量连续输注(6g/天)的群体 PTA 高 4%。虽然哌拉西林的肾消除在治疗浓度下呈饱和状态,但非肾清除的饱和程度较小。饱和消除对临床相关剂量方案的 PTA 的影响相对较小。